期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
48例宫颈残端恶性肿瘤预后因素分析
1
作者 穆叶赛 阿依努尔·色义提 古丽娜·库尔班 《中华放射肿瘤学杂志》 CSCD 北大核心 2019年第11期840-842,共3页
目的探讨影响宫颈残端恶性肿瘤不良预后因素,为临床诊疗提供一定参考。方法回顾分析2005-2016年间本医院收治的48例宫颈残端恶性肿瘤患者临床资料。ⅠA-ⅡA期19例(40%)以手术+辅助治疗为主,ⅡB-Ⅳ期29例(60%)以放化疗为主。中位发病年... 目的探讨影响宫颈残端恶性肿瘤不良预后因素,为临床诊疗提供一定参考。方法回顾分析2005-2016年间本医院收治的48例宫颈残端恶性肿瘤患者临床资料。ⅠA-ⅡA期19例(40%)以手术+辅助治疗为主,ⅡB-Ⅳ期29例(60%)以放化疗为主。中位发病年龄51岁,子宫次全切除原因以子宫肌瘤为主,距子宫次全切除平均时间10.76年。结果1、3、5年生存率分别为98%、83%、74%。单因素分析显示距子宫次全切除时间(P=0.016)、肿瘤直径(P=0.016)、临床分期(P=0.036)、组织学分级(P=0.009)、淋巴结转移(P=0.044)、宫旁受侵(P=0.046)、骨髓抑制(P=0.013)、根治性手术(P=0.019)为不良预后影响因素。结论宫颈残端恶性肿瘤不良预后与肿瘤直径、临床分期、组织学分级、淋巴结转移、宫旁受侵、骨髓抑制有关,其中组织学分级是独立危险因素。 展开更多
关键词 宫颈残端 恶性肿瘤/放化疗法 预后
原文传递
Chemoradiotherapy for a patient with a giant esophageal fistula 被引量:2
2
作者 Takuma Nomiya Kazuhide Teruyama +1 位作者 Hitoshi Wada Kenji Nemoto 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第15期2250-2254,共5页
We describe our experience of treatment for a giant esophageal malignant fistula, which has not been reported previously. A 36-year-old woman who was diagnosed as having massive esophageal small cell carcinoma with me... We describe our experience of treatment for a giant esophageal malignant fistula, which has not been reported previously. A 36-year-old woman who was diagnosed as having massive esophageal small cell carcinoma with metastases was treated with chemoradiotherapy. However, a giant esophagomediastinal fistula appeared due to shrinkage of the massive tumor, and all anti-cancer treatment was suspended. However, chemoradiotherapy was restarted at the request of the patient despite the presence of the fistula. After restarting treatment, the giant esophageal fistula was naturally closed despite intensive chemoradiotherapy, and the patient became able to eat and drink. Although the patient finally died, her QOL and prognosis seemed to be improved by the chemoradiotherapy. Anti-cancer treatment could be safely performed despite the presence of a giant fistula. The giant fistula closed while intensive chemotherapy was administered to the patient. Therefore, the presence of a fistula may not be a contraindication for curative chemoradiotherapy. Completion of treatment with proper management and maintenance of patients would be of benefit to patients with fistula. 展开更多
关键词 Esophageal malignancy Esophageal fistula CHEMOTHERAPY Radiation therapy Small cell carcinoma
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部